Literature DB >> 24440548

Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

Sean Ekins1, Allen C Casey2, David Roberts2, Tanya Parish2, Barry A Bunin3.   

Abstract

The search for compounds active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells. We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compounds prior to in vitro testing. We used this to select and test 48 compounds in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%. Among the hits, we identified several compounds belonging to the same series including five quinolones (including ciprofloxacin), three molecules with long aliphatic linkers and three singletons. This approach represents a rapid method to prioritize compounds for testing that can be used alongside medicinal chemistry insight and other filters to identify active molecules. Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen. In addition, the potential targets for the 11 molecules were predicted using TB Mobile and clustering alongside a set of over 740 molecules with known M. tuberculosis target annotations. These predictions may serve as a mechanism for prioritizing compounds for further optimization.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bayesian models; Collaborative drug discovery tuberculosis database; Function class fingerprints; Mycobacterium tuberculosis; Virtual screening

Mesh:

Substances:

Year:  2013        PMID: 24440548      PMCID: PMC4394018          DOI: 10.1016/j.tube.2013.12.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  51 in total

1.  Totally drug-resistant tuberculosis in India.

Authors:  Zarir F Udwadia; Rohit A Amale; Kanchan K Ajbani; Camilla Rodrigues
Journal:  Clin Infect Dis       Date:  2011-12-21       Impact factor: 9.079

2.  Chemical space: missing pieces in cheminformatics.

Authors:  Sean Ekins; Rishi R Gupta; Eric Gifford; Barry A Bunin; Chris L Waller
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

3.  Improved naïve Bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction.

Authors:  Anthony E Klon; Jeffrey F Lowrie; David J Diller
Journal:  J Chem Inf Model       Date:  2006 Sep-Oct       Impact factor: 4.956

4.  Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Authors:  Andreas Bender; Josef Scheiber; Meir Glick; John W Davies; Kamal Azzaoui; Jacques Hamon; Laszlo Urban; Steven Whitebread; Jeremy L Jenkins
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

Review 5.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

6.  A collaborative database and computational models for tuberculosis drug discovery.

Authors:  Sean Ekins; Justin Bradford; Krishna Dole; Anna Spektor; Kellan Gregory; David Blondeau; Moses Hohman; Barry A Bunin
Journal:  Mol Biosyst       Date:  2010-02-09

7.  Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans.

Authors:  C A Hitchcock; K Dickinson; S B Brown; E G Evans; D J Adams
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

8.  SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.

Authors:  Kapil Tahlan; Regina Wilson; David B Kastrinsky; Kriti Arora; Vinod Nair; Elizabeth Fischer; S Whitney Barnes; John R Walker; David Alland; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

9.  Antituberculosis activity of the molecular libraries screening center network library.

Authors:  Joseph A Maddry; Subramaniam Ananthan; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Clinton Maddox; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Melinda I Sosa; E Lucile White; Wei Zhang
Journal:  Tuberculosis (Edinb)       Date:  2009-09-26       Impact factor: 3.131

10.  A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.

Authors:  Juliane Ollinger; Mai Ann Bailey; Garrett C Moraski; Allen Casey; Stephanie Florio; Torey Alling; Marvin J Miller; Tanya Parish
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more
  21 in total

1.  High-throughput screening and Bayesian machine learning for copper-dependent inhibitors of Staphylococcus aureus.

Authors:  Alex G Dalecki; Kimberley M Zorn; Alex M Clark; Sean Ekins; Whitney T Narmore; Nichole Tower; Lynn Rasmussen; Robert Bostwick; Olaf Kutsch; Frank Wolschendorf
Journal:  Metallomics       Date:  2019-03-20       Impact factor: 4.526

Review 2.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 3.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

4.  A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.

Authors:  Kimberley M Zorn; Shengxi Sun; Cecelia L McConnon; Kelley Ma; Eric K Chen; Daniel H Foil; Thomas R Lane; Lawrence J Liu; Nelly El-Sakkary; Danielle E Skinner; Sean Ekins; Conor R Caffrey
Journal:  ACS Infect Dis       Date:  2021-01-12       Impact factor: 5.084

5.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

6.  Data Mining and Computational Modeling of High-Throughput Screening Datasets.

Authors:  Sean Ekins; Alex M Clark; Krishna Dole; Kellan Gregory; Andrew M Mcnutt; Anna Coulon Spektor; Charlie Weatherall; Nadia K Litterman; Barry A Bunin
Journal:  Methods Mol Biol       Date:  2018

7.  Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets.

Authors:  Alexandru Korotcov; Valery Tkachenko; Daniel P Russo; Sean Ekins
Journal:  Mol Pharm       Date:  2017-11-13       Impact factor: 4.939

Review 8.  Learning from the past for TB drug discovery in the future.

Authors:  Katarína Mikušová; Sean Ekins
Journal:  Drug Discov Today       Date:  2016-10-04       Impact factor: 7.851

9.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

10.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.